{"schema_version":"secwatch.filing_event.v1","accession":"0000950170-23-057440","form_type":"8-K","ticker":"AMWL","cik":"0001393584","company_name":"American Well Corp","filed_at":"2023-11-01T23:59:59+00:00","discovered_at":"2026-05-14T18:03:28.845559+00:00","generated_at":"2026-06-09T02:13:49.206334+00:00","sec_items":["2.02","9.01"],"event_type":"earnings","sentiment":"neutral","materiality_score":0.75,"calibrated_materiality_score":0.75,"confidence":"high","headline":"Amwell Q3 revenue $61.9M, net loss $137.1M includes $78.9M goodwill impairment; guidance revised","bullets":["Revenue $61.9M (subscription $28.4M, AMG visit revenue $26.7M); gross margin 35%.","Net loss $137.1M vs. $93.5M in Q2 2023, primarily from $78.9M non-cash goodwill impairment.","Adjusted EBITDA improved to ($38.5M) from ($45.3M) in Q2; cash and short-term securities $418.1M.","Total visits 1.4M; Converge platform visits reached 50% of total vs. 43% in Q2.","2023 guidance: revenue $257-263M; Adjusted EBITDA now ($162M) to ($167M), reflecting Defense Health Agency win investment."],"urls":{"canonical":"https://secwatch.observer/filing/0000950170-23-057440","json":"https://secwatch.observer/filing/0000950170-23-057440.json","markdown":"https://secwatch.observer/filing/0000950170-23-057440.md","text":"https://secwatch.observer/filing/0000950170-23-057440.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1393584/000095017023057440/0000950170-23-057440-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1393584/000095017023057440/amwl-20231101.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-09T02:13:49.206334+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[{"claim_id":"9c657f5fa799556e3685385040fc9aa5563469e1","claim":"American Well Corp reported third quarter ended Sept. 30, 2023 results: revenue $61.9 million, net income ($137.1) million. Guidance reaffirmed.","evidence_excerpt":"leader in hybrid care enablement, today announced financial results for the third quarter ended Sept. 30, 2023. Amwell Third Quarter 2023 Highlights: • Recorded Total Revenue of $61.9 million o Achieved subscription revenue of $28.4 million o Recorded Amwell Medical Group (“AMG”) visit revenue of $26.7 million • Reported gross margin of 35% • Net loss was ($137.1)","evidence_source":"SEC 8-K Item 2.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1393584/000095017023057440/0000950170-23-057440-index.htm","confidence":0.95,"family_label":"Earnings Releases","details":[{"label":"Period","value":"third quarter ended Sept. 30, 2023"},{"label":"Revenue","value":"$61.9 million"},{"label":"Net income","value":"($137.1) million"},{"label":"Guidance","value":"reaffirmed"},{"label":"Result","value":"reported results"}],"fact_type":"earnings_release"}],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}